Moderna Inc (MRNA) - Total Liabilities
Based on the latest financial reports, Moderna Inc (MRNA) has total liabilities worth $4.20 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MRNA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Moderna Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Moderna Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see MRNA asset base.
Moderna Inc Competitors by Total Liabilities
The table below lists competitors of Moderna Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ASS.GENERALI ADR 1/2/EO 1
F:ASG0
|
Germany | €546.31 Billion |
|
KDDI CORP.UNSP.ADR 4
F:DIP0
|
Germany | €13.47 Trillion |
|
Societe Generale S.A.
PA:GLE
|
France | €1.47 Trillion |
|
Investor AB ser. A
ST:INVE-A
|
Sweden | Skr163.19 Billion |
|
Devon Energy Corporation
NYSE:DVN
|
USA | $17.11 Billion |
|
Public Storage
NYSE:PSA
|
USA | $10.83 Billion |
|
China Citic Bank Corp Ltd Class A
SHG:601998
|
China | CN¥9.37 Trillion |
|
Rheinmetall AG
F:RHM
|
Germany | €11.16 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Moderna Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See MRNA equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Moderna Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Moderna Inc (2014–2025)
The table below shows the annual total liabilities of Moderna Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.69 Billion | +13.79% |
| 2024-12-31 | $3.24 Billion | -29.11% |
| 2023-12-31 | $4.57 Billion | -32.12% |
| 2022-12-31 | $6.74 Billion | -36.00% |
| 2021-12-31 | $10.52 Billion | +120.35% |
| 2020-12-31 | $4.78 Billion | +1051.92% |
| 2019-12-31 | $414.61 Million | -4.00% |
| 2018-12-31 | $431.91 Million | -5.94% |
| 2017-12-31 | $459.19 Million | -20.18% |
| 2016-12-31 | $575.31 Million | +335039.20% |
| 2015-12-31 | $171.66K | -98.74% |
| 2014-12-31 | $13.59 Million | -- |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more